

Evelyne Jacqz Aigrain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4447612/publications.pdf>

Version: 2024-02-01

284
papers

8,731
citations

53794

45
h-index

69250

77
g-index

313
all docs

313
docs citations

313
times ranked

7338
citing authors

#	ARTICLE	IF	CITATIONS
1	A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). <i>Journal of General Internal Medicine</i> , 2021, 36, 3179-3187.	2.6	575
2	Nomenclature for human CYP2D6 alleles. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 193-201.	5.7	403
3	Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. <i>Early Human Development</i> , 2012, 88, S69-S74.	1.8	382
4	Expression of CYP2D6 in developing human liver. <i>FEBS Journal</i> , 1991, 202, 583-588.	0.2	180
5	Population pharmacokinetics of midazolam in neonates. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 615-625.	4.7	158
6	Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 609-618.	4.7	142
7	Ciprofloxacin safety in paediatrics: a systematic review. <i>Archives of Disease in Childhood</i> , 2011, 96, 874-880.	1.9	137
8	Risks and Benefits of Nonsteroidal Anti-Inflammatory Drugs in Children. <i>Paediatric Drugs</i> , 2001, 3, 817-858.	3.1	133
9	LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1603-1607.	3.3	133
10	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. <i>Pharmacogenetics and Genomics</i> , 1993, 3, 197-204.	5.7	132
11	Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. <i>Lancet, The</i> , 1994, 344, 646-650.	13.7	120
12	Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. <i>Xenobiotica</i> , 1992, 22, 671-680.	1.1	105
13	Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 575-584.	2.4	104
14	Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. <i>Archives of Disease in Childhood</i> , 2013, 98, 449-453.	1.9	104
15	Pharmacokinetics of midazolam in critically ill neonates. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 191-192.	1.9	96
16	Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 329-32.	1.9	93
17	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1068-1080.	2.4	92
18	Association Between Pulmonary Ureaplasma Colonization and Bronchopulmonary Dysplasia in Preterm Infants. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 697-702.	2.0	84

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacokinetics of Sedatives in Neonates. <i>Clinical Pharmacokinetics</i> , 1996, 31, 423-443.	3.5	82
20	Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. <i>British Journal of Anaesthesia</i> , 2007, 98, 372-379.	3.4	78
21	Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. <i>Haematologica</i> , 2008, 93, 502-510.	3.5	74
22	Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 89-96.	1.9	72
23	Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2000-2013.	6.1	72
24	Diclofenac and metabolite pharmacokinetics in children. <i>Paediatric Anaesthesia</i> , 2004, 14, 443-451.	1.1	71
25	Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 710-712.	2.3	68
26	Renal transplantation in children: Critical analysis of age related surgical complications. <i>Pediatric Transplantation</i> , 2010, 14, 512-519.	1.0	68
27	Ciprofloxacin Use in Neonates. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e29-e37.	2.0	67
28	Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. <i>Archives of Disease in Childhood</i> , 2015, 100, 394-398.	1.9	65
29	Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1273-1285.	3.5	65
30	Hypotension with midazolam and fentanyl in the newborn. <i>Lancet, The</i> , 1991, 337, 1545-1546.	13.7	62
31	Prevention of Nosocomial Infections in Neonatal Intensive Care Units. <i>American Journal of Perinatology</i> , 2013, 30, 081-088.	1.4	62
32	Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3191-3199.	3.2	62
33	Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1280-1291.	2.0	61
34	Maternal Immune Response and Neonatal Seroprotection From a Single Dose of a Monovalent Nonadjuvanted 2009 Influenza A(H1N1) Vaccine. <i>Annals of Internal Medicine</i> , 2011, 155, 733.	3.9	60
35	Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. <i>Gastroenterology</i> , 1995, 108, 470-476.	1.3	59
36	Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1397-1402.	3.7	59

#	ARTICLE	IF	CITATIONS
37	Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. <i>Seminars in Fetal and Neonatal Medicine</i> , 2013, 18, 28-34.	2.3	59
38	Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 189-195.	1.9	56
39	Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 1-8.	2.4	55
40	Population Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Pediatric and Adolescent Patients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 378-388.	2.0	54
41	A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 609-620.	2.3	52
42	Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. <i>Pediatric Nephrology</i> , 2000, 14, 95-99.	1.7	51
43	Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1233-1242.	1.9	49
44	Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. <i>Pediatric Nephrology</i> , 2012, 27, 389-396.	1.7	48
45	Neonatal fungal infections: when to treat?. <i>Early Human Development</i> , 2012, 88, S6-S10.	1.8	47
46	Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 793-800.	2.4	46
47	Pain control: Non-steroidal anti-inflammatory agents. <i>Seminars in Fetal and Neonatal Medicine</i> , 2006, 11, 251-259.	2.3	46
48	Use and safety of azithromycin in neonates: a systematic review. <i>BMJ Open</i> , 2015, 5, e008194.	1.9	46
49	Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. <i>Journal of Pediatrics</i> , 1992, 121, 608-613.	1.8	44
50	Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. <i>Pediatric Nephrology</i> , 2012, 27, 1249-1256.	1.7	44
51	Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2039-2042.	3.2	44
52	Maternal smoking during pregnancy and nicotine and cotinine concentrations in maternal and neonatal hair. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002, 109, 909-911.	2.3	42
53	Cellular Immune Response of Fetuses to Cytomegalovirus. <i>Pediatric Research</i> , 2004, 55, 280-286.	2.3	41
54	A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults. <i>Clinical Pharmacokinetics</i> , 2013, 52, 555-565.	3.5	41

#	ARTICLE	IF	CITATIONS
55	Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6572-6580.	3.2	41
56	Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1197-1207.	2.4	41
57	Are Cytochrome P450 CYP2C8 and CYP2C9 Polymorphisms Associated with Ibuprofen Response in Very Preterm Infants?. <i>PLoS ONE</i> , 2010, 5, e12329.	2.5	39
58	Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children. <i>Current Drug Metabolism</i> , 2012, 13, 822-834.	1.2	39
59	Cytochrome P450-Dependent Metabolism of Dextromethorphan: Fetal and Adult Studies. <i>Developmental Pharmacology and Therapeutics</i> , 1992, 18, 161-168.	0.2	38
60	Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 96-102.	2.0	38
61	Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 454-464.	2.4	38
62	Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. <i>Pediatric Nephrology</i> , 2010, 25, 965-969.	1.7	37
63	Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. <i>Pediatric Nephrology</i> , 2014, 29, 2325-2331.	1.7	37
64	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 992-1002.	3.0	37
65	Drug policy in Europe. <i>Early Human Development</i> , 2011, 87, S27-S30.	1.8	36
66	N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients [letter]. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 581-582.	2.4	35
67	Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. <i>Leukemia</i> , 2001, 15, 1706-1712.	7.2	35
68	Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 48-55.	2.0	35
69	Melatonin Levels in Preterm and Term Infants and Their Mothers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2077.	4.1	35
70	Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2003, 18, 943-948.	1.7	34
71	Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3170-3178.	3.2	34
72	Excretion of Ketoprofen and Nalbuphine in Human Milk During Treatment of Maternal Pain After Delivery. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 815-818.	2.0	34

#	ARTICLE	IF	CITATIONS
73	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 358-366.	2.4	34
74	Safety of fluconazole in paediatrics: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1211-1221.	1.9	34
75	High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. <i>Biomedical Applications</i> , 1999, 721, 147-152.	1.7	33
76	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2128-2138.	3.0	33
77	Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 688-699.	2.0	32
78	European survey on the use of prophylactic fluconazole in neonatal intensive care units. <i>European Journal of Pediatrics</i> , 2012, 171, 439-445.	2.7	32
79	Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. <i>Biomedical Applications</i> , 1998, 709, 47-56.	1.7	31
80	Intravenous Omeprazole in Children: Pharmacokinetics and Effect on 24-Hour Intra-gastric pH. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 144-148.	1.8	31
81	Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. <i>Biomedical Applications</i> , 2001, 763, 61-69.	1.7	31
82	Pharmacokinetics of intravenous omeprazole in children. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 181-5.	1.9	30
83	CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 121-124.	2.4	30
84	Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. <i>Reproductive Toxicology</i> , 2005, 20, 573-574.	2.9	30
85	Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. <i>European Journal of Pediatrics</i> , 2015, 174, 481-491.	2.7	30
86	DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. <i>Human Genetics</i> , 1994, 94, 401-6.	3.8	29
87	Determination of ketamine and norketamine in plasma by micro-liquid chromatography-mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 171-176.	2.8	29
88	Principles of Therapeutic Drug Monitoring. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 77-90.	1.8	29
89	Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1127-1134.	3.5	29
90	Choosing the right dose of tacrolimus. <i>Archives of Disease in Childhood</i> , 2015, 100, 406-413.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	29
92	Cotrimoxazole for Prenatal Treatment of Congenital Toxoplasmosis?. <i>Parasitology Today</i> , 2000, 16, 254-256.	3.0	28
93	Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 905-922.	3.5	28
94	Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 515-522.	1.5	28
95	Antifungal prophylaxis in neonates. <i>Early Human Development</i> , 2011, 87, S59-S60.	1.8	28
96	How to use vancomycin optimally in neonates: remaining questions. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 635-648.	3.1	28
97	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	28
98	Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1748-1756.	2.4	27
99	Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encaïnide in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1992, 263, 780-6.	2.5	27
100	Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 507-512.	4.7	26
101	Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 583-592.	4.7	26
102	Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 633-639.	1.5	26
103	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-36 months. <i>Antiviral Therapy</i> , 2010, 15, 297-305.	1.0	26
104	A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6626-6634.	3.2	26
105	Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1989-1999.	2.4	26
106	Influence of amiodarone on genetically determined drug metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 259-266.	4.7	25
107	Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. <i>European Journal of Clinical Pharmacology</i> , 1997, 53, 71-74.	1.9	25
108	Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 321-328.	3.5	25

#	ARTICLE	IF	CITATIONS
109	Cystatin C as a potential biomarker for dosing of renally excreted drugs. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 20-27.	2.4	25
110	Predicting CYP3A4-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 358-368.	2.4	25
111	Sepsis in young infants with congenital heart disease. <i>Early Human Development</i> , 2012, 88, S92-S97.	1.8	24
112	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. <i>Pediatric Nephrology</i> , 2008, 23, 1859-1865.	1.7	23
113	Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 681-687.	2.0	23
114	Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research. <i>PLoS ONE</i> , 2019, 14, e0222667.	2.5	23
115	mRNA Expression of MDR1 and Major Metabolising Enzymes in Human Fetal Tissues. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 529-536.	2.2	22
116	Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates. <i>Biomedical Chromatography</i> , 2011, 25, 827-832.	1.7	22
117	Study of the B cell response to cytochrome P450IID6 in sera from chronic hepatitis C patients. <i>Clinical and Experimental Immunology</i> , 1996, 106, 336-343.	2.6	21
118	The use of fluconazole in neonatal intensive care units. <i>Archives of Disease in Childhood</i> , 2009, 94, 983-987.	1.9	21
119	The management of <i>Candida</i> infections in preterm neonates and the role of micafungin. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011, 24, 24-27.	1.5	21
120	Individualization of Valganciclovir Prophylaxis for Cytomegalovirus Infection in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 326-330.	2.0	21
121	Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. <i>Diagnostic Microbiology and Infectious Disease</i> , 1989, 12, 87-91.	1.8	20
122	Recruitment in pediatric clinical research was influenced by study characteristics and pediatricians' perceptions: a multicenter survey. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 1151-1157.	5.0	20
123	Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	20
124	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1435-1448.	3.5	20
125	Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 61-5.	1.9	19
126	Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 555-560.	1.9	19

#	ARTICLE	IF	CITATIONS
127	Neonatal drug trials: impact of EU and US paediatric regulations. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, F438-F438.	2.8	19
128	UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum—Application to pediatric studies. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 256-262.	2.8	19
129	Pharmacokinetics of the S(+) and R(−) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. British Journal of Clinical Pharmacology, 1997, 44, 183-185.	2.4	18
130	Fluconazole use and safety in the nursery. Early Human Development, 2012, 88, S11-S15.	1.8	18
131	Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. Biomedical Applications, 1989, 495, 361-363.	1.7	17
132	Perinatal adverse effects of nalbuphine given during parturition. Lancet, The, 1990, 335, 1588.	13.7	17
133	Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. British Journal of Clinical Pharmacology, 2014, 77, 861-872.	2.4	17
134	Licensed medicines, off-label use or evidence-based. Which is most important?. Archives of Disease in Childhood, 2017, 102, 53-54.	1.9	17
135	Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. Sleep Medicine, 2020, 66, 220-226.	1.6	17
136	Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug-Induced Hepatotoxicity in Chinese Pediatric Patients. PLoS ONE, 2014, 9, e115410.	2.5	17
137	Cytochrome P450IID subfamily in non-human primates. Biochemical Pharmacology, 1991, 41, 1657-1663.	4.4	16
138	Effects of drugs on the fetus. Seminars in Fetal and Neonatal Medicine, 2005, 10, 139-147.	2.3	16
139	Role of echinocandins in the management of fungal infections in neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 49-52.	1.5	16
140	Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. Early Human Development, 2012, 88, S60-S64.	1.8	16
141	Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. British Journal of Clinical Pharmacology, 2016, 82, 1058-1068.	2.4	16
142	Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. British Journal of Clinical Pharmacology, 2018, 84, 997-1005.	2.4	16
143	Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial. Transplantation, 2010, 89, 1255-1262.	1.0	15
144	Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. European Journal of Clinical Pharmacology, 2013, 69, 1031-1036.	1.9	15

#	ARTICLE	IF	CITATIONS
145	Safety study of Ciprofloxacin in newborn mice. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 74, 161-169.	2.7	15
146	High Prevalence of Polycystic Ovary Syndrome in Type 1 Diabetes Mellitus Adolescents: Is There a Difference Depending on the NIH and Rotterdam Criteria?. <i>Hormone Research in Paediatrics</i> , 2017, 87, 333-341.	1.8	15
147	Clinical trials in neonates: How to optimise informed consent and decision making? A European Delphi survey of parent representatives and clinicians. <i>PLoS ONE</i> , 2018, 13, e0198097.	2.5	15
148	Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
149	Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 257-263.	4.7	14
150	Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions. <i>Biomedical Applications</i> , 1997, 700, 275-277.	1.7	14
151	Intravesical Morphine Analgesia Is Not Effective After Bladder Surgery in Children: Results of A Randomized Double-Blind Study. <i>Journal of Urology</i> , 2002, 168, 694-697.	0.4	14
152	The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 653-658.	2.3	14
153	Azithromycin, <i>Ureaplasma</i> and chronic lung disease of prematurity: a case study for neonatal drug development: Figure 1. <i>Archives of Disease in Childhood</i> , 2012, 97, 573-577.	1.9	14
154	First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro "In Silico" Data Predictive of Neonatal Pharmacokinetics of Fluconazole. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1005-1018.	3.5	14
155	Dosage individualization in children: integration of pharmacometrics in clinical practice. <i>World Journal of Pediatrics</i> , 2014, 10, 197-203.	1.8	14
156	Gastrointestinal tolerance of erythritol-containing beverage in young children: a double-blind, randomised controlled trial. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 746-751.	2.9	14
157	A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the "preselected prescription"™ concept at the bedside. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 64-68.	1.5	14
158	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. <i>Pharmacological Research</i> , 2010, 61, 167-174.	7.1	13
159	Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. <i>Pharmacogenomics</i> , 2011, 12, 827-843.	1.3	13
160	Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 739-741.	2.0	13
161	Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1181-1185.	1.9	13
162	Population pharmacokinetics of abacavir in infants, toddlers and children. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1525-1535.	2.4	13

#	ARTICLE	IF	CITATIONS
163	Randomized controlled trials of antibiotics for neonatal infections: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 21-29.	2.4	13
164	Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 969-975.	6.1	13
165	Precision therapy of 6â€œmercaptopurine in Chinese children with acute lymphoblastic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1519-1527.	2.4	13
166	Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child. <i>Transplantation</i> , 2012, 93, e29-e30.	1.0	12
167	Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
168	Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
169	Pharmacokinetics of ganciclovir in renal transplant children. <i>Pediatric Nephrology</i> , 1992, 6, 194-196.	1.7	11
170	DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. <i>Human Genetics</i> , 1993, 92, 367-372.	3.8	11
171	Fetal thyroid goiter after massive iodine exposure. <i>Prenatal Diagnosis</i> , 2004, 24, 751-753.	2.3	11
172	Effects of Recombinant Human Growth Hormone for 1 Year on Body Composition and Muscle Strength in Children on Long-Term Steroid Therapy: Randomized Controlled, Delayed-Start Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2746-2754.	3.6	11
173	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
174	Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A postâ€œmarketing study to support paediatric labelling in China. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1155-1164.	2.4	11
175	Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 699-709.	3.0	11
176	Population Pharmacokinetics of Nalbuphine in Neonates. <i>Paediatric and Perinatal Drug Therapy</i> , 2003, 5, 190-198.	0.5	11
177	Pathologic and laboratory correlation in microcephaly associated with prenatal cocaine exposure. <i>Early Human Development</i> , 2001, 63, 79-81.	1.8	10
178	Population pharmacokinetics and maximum <i>a posteriori</i> probability Bayesian estimator of abacavir: application of individualized therapy in HIVâ€œinfected infants and toddlers. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 641-650.	2.4	10
179	A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate. <i>Hormone Research in Paediatrics</i> , 2016, 86, 188-195.	1.8	10
180	Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. <i>Pediatric Nephrology</i> , 2018, 33, 1045-1055.	1.7	10

#	ARTICLE	IF	CITATIONS
181	Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study. Archives of Disease in Childhood, 2018, 103, 772-775.	1.9	10
182	A Delphi Process to Optimize Quality and Performance of Drug Evaluation in Neonates. PLoS ONE, 2014, 9, e104976.	2.5	10
183	Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis.. British Journal of Clinical Pharmacology, 1990, 30, 153-154.	2.4	9
184	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. PLoS ONE, 2016, 11, e0166207.	2.5	9
185	Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Research, 2016, 132, 111-115.	4.1	9
186	Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. European Journal of Pharmaceutical Sciences, 2016, 83, 1-7.	4.0	9
187	Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children. Clinical Drug Investigation, 2018, 38, 157-171.	2.2	9
188	Launch of a European paediatric clinical trials register. Paediatric and Perinatal Drug Therapy, 2004, 6, 38-39.	0.5	9
189	Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese [letter]. British Journal of Clinical Pharmacology, 1991, 32, 135-136.	2.4	8
190	Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression. British Journal of Clinical Pharmacology, 2009, 68, 770-772.	2.4	8
191	How to Optimize the Evaluation and Use of Antibiotics in Neonates. Pediatric Clinics of North America, 2012, 59, 1117-1128.	1.8	8
192	Correct choices for correct treatments: key issues in the management of Candida infections in preterm neonates. Early Human Development, 2012, 88, S98-S100.	1.8	8
193	The Importance of Knowing How Vancomycin is Measured When Interpreting Its Pharmacokinetic Results. Therapeutic Drug Monitoring, 2013, 35, 416.	2.0	8
194	Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Design, Development and Therapy, 2014, 8, 2321.	4.3	8
195	Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2017, 83, 1287-1297.	2.4	8
196	Early target attainment of azithromycin therapy in children with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 2846-2850.	3.0	8
197	Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	8
198	Candida colonization in the nursery. Jornal De Pediatria, 2012, 88, 187-90.	2.0	8

#	ARTICLE	IF	CITATIONS
199	Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. <i>Developmental Pharmacology and Therapeutics</i> , 1992, 18, 161-8.	0.2	8
200	Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 161-165.	2.4	7
201	Presentation of the French Network of Paediatric Clinical Investigation Centres (CIC.P). <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 105-110.	1.9	7
202	Neonatal cutaneous disseminated aspergillosis in a preterm extremely-low-birth-weight infant with favourable outcome at 3-year follow-up: a case report. <i>Early Human Development</i> , 2012, 88, S65-S68.	1.8	7
203	Ureaplasma, bronchopulmonary dysplasia and azithromycin in European neonatal intensive care units: a survey. <i>Scientific Reports</i> , 2014, 4, 4076.	3.3	7
204	Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	7
205	Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3423-3429.	3.0	7
206	Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 274-284.	2.4	7
207	Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. <i>Therapie</i> , 2021, 76, 675-685.	1.0	7
208	Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 472-480.	2.0	7
209	Informed consent for neonatal trials: practical points to consider and a check list. <i>BMJ Paediatrics Open</i> , 2020, 4, e000847.	1.4	7
210	Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 49-59.	5.6	7
211	Toxic epidermal necrolysis due to paediatric erythromycin/sulfisoxazole combination. <i>Lancet</i> , The, 1990, 336, 1010-1011.	13.7	6
212	Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy- tert -Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 525-535.	3.2	6
213	The DEC-net European register of paediatric drug therapy trials: contents and context. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 611-617.	1.9	6
214	An optimal LC-MS/MS method for determination of azithromycin in white blood cells: application to pediatric samples. <i>Bioanalysis</i> , 2014, 6, 2317-2328.	1.5	6
215	A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 852-860.	2.4	6
216	Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1150-1151.	3.0	6

#	ARTICLE	IF	CITATIONS
217	Fluconazole prophylaxis in neonates. Archives of Disease in Childhood, 2015, 100, 75-76.	1.9	6
218	Drug evaluation in children 10 years after the European pediatric regulation current challenges and perspectives. Therapie, 2018, 73, 113-117.	1.0	6
219	Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia. European Journal of Clinical Pharmacology, 2020, 76, 1547-1556.	1.9	6
220	Developmental population pharmacokineticsâ€“pharmacodynamics and dosing optimization of cefoperazone in children. Journal of Antimicrobial Chemotherapy, 2020, 75, 1917-1924.	3.0	6
221	An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90â€“days (NeoVanc): study protocol for a randomised controlled trial. Trials, 2020, 21, 329.	1.6	6
222	Assessment of CYP2D6 activity in very elderly healthy subjects. Fundamental and Clinical Pharmacology, 1996, 10, 158-159.	1.9	5
223	Optimizing Micafungin Dosing in Children. Pediatric Infectious Disease Journal, 2012, 31, 1211-1212.	2.0	5
224	Pharmacogenetics of posttransplant diabetes mellitus. Pharmacogenomics Journal, 2017, 17, 209-221.	2.0	5
225	Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4578-4587.	3.6	5
226	Pharmacogenetics: Applications to Pediatric Patients. Advances in Pharmacology, 2018, 83, 191-215.	2.0	5
227	Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial. Neonatology, 2019, 115, 142-148.	2.0	5
228	Paediatric clinical research in Europe: an insight on expertsâ€™ needs and perspectives. Contemporary Clinical Trials Communications, 2021, 21, 100735.	1.1	5
229	Genetic Polymorphisms of Drug Metabolism. Developmental Pharmacology and Therapeutics, 1989, 13, 78-84.	0.2	4
230	Population pharmacokinetics and dosing optimization of cefthiamidine in children with hematologic infection. Drug Design, Development and Therapy, 2018, Volume 12, 855-862.	4.3	4
231	Body Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
232	Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2020, 75, 2232-2239.	3.0	4
233	Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates. Frontiers in Pharmacology, 2021, 12, 634686.	3.5	4
234	Drug Safety in Translational Paediatric Research: Practical Points to Consider for Paediatric Safety Profiling and Protocol Development: A Scoping Review. Pharmaceutics, 2021, 13, 695.	4.5	4

#	ARTICLE	IF	CITATIONS
235	Drug versus placebo randomized controlled trials in neonates: A review of ClinicalTrials.gov registry. PLoS ONE, 2017, 12, e0171760.	2.5	4
236	Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation. Clinical Pharmacokinetics, 2022, 61, 1027-1038.	3.5	4
237	Monoclonal antibody fluorescent polarisation immunoassay versus ¹²⁵ Iode labelled ligand radioimmunoassay for the measurement of cyclosporine concentrations in whole blood. Fundamental and Clinical Pharmacology, 1991, 5, 557-562.	1.9	3
238	Monitoring azathioprine therapy in pediatric renal transplant patients with red blood cell thiopurine methyltransferase. Transplantation Proceedings, 2000, 32, 361-363.	0.6	3
239	<scp>mRNA</scp> expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood. Fundamental and Clinical Pharmacology, 2018, 32, 422-435.	1.9	3
240	Pharmacogenetics and application in pediatrics. Therapie, 2018, 73, 157-163.	1.0	3
241	Sequential analysis in neonatal researchâ€”systematic review. European Journal of Pediatrics, 2018, 177, 733-740.	2.7	3
242	Principles and applications of pharmacometrics in drug evaluation in children. Therapie, 2018, 73, 165-170.	1.0	3
243	<p>Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4405-4411.	4.3	3
244	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. British Journal of Clinical Pharmacology, 2022, , .	2.4	3
245	Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systemic lupus erythematosus. European Journal of Clinical Pharmacology, 2022, 78, 1003-1010.	1.9	3
246	MÃ©thodologie de lâ€™Ã©valuation des mÃ©dicaments chez la femme enceinte. Therapie, 2003, 58, 247-252.	1.0	2
247	Risk Management and Monitoring Methods for the Future Mother, Embryo, Fetus, and post-natal Consequences. Therapie, 2006, 61, 297-304.	1.0	2
248	Safety of ciprofloxacin in neonates with sepsis. Adverse Drug Reaction Bulletin, 2010, &NA;, 1019-1022.	0.5	2
249	Authorâ€™s Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. Clinical Pharmacokinetics, 2015, 54, 1289-1291.	3.5	2
250	Principes de pharmacologie pÃ©diatrique. , 2007, , 22-30.		2
251	Echinocandins for the Nursery: An Update. Current Drug Metabolism, 2013, 14, 203-207.	1.2	2
252	Editorial Commentary: Effectiveness or Efficacy: Which Study to Evaluate Antibiotics in Neonates?. Clinical Infectious Diseases, 2012, 55, 1503-1504.	5.8	1

#	ARTICLE	IF	CITATIONS
253	Capacities and Competences for Drug Evaluation in European Neonatal Intensive Care Units: A Survey and Key Issues for Improvement. <i>American Journal of Perinatology</i> , 2018, 35, 589-598.	1.4	1
254	Reporting of offspring data in diabetes, HIV infection and hypertension trials during pregnancy: a systematic review. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020, 105, 215-221.	2.8	1
255	Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 74-77.	1.5	1
256	Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis. <i>Frontiers in Pharmacology</i> , 2021, 12, 624662.	3.5	1
257	Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 635345.	3.5	1
258	Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole. <i>Current Drug Metabolism</i> , 2013, 14, 193-202.	1.2	1
259	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Blood</i> , 2017, 130, 975-975.	1.4	1
260	Molecular genetics of cytochrome P450 IID. <i>Clinical Reviews in Allergy and Immunology</i> , 1995, 13, 211-221.	6.5	1
261	Catégorie moléculaire du cytochrome P450 IID : anomalies du métabolisme des médicaments. <i>Revue Française D'allergologie Et D'immunologie Clinique</i> , 1995, 35, 462-469.	0.1	0
262	Population pharmacokinetic model for nelfinavir and its active metabolite hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P15.	4.7	0
263	Pharmacogenetics of CYP3A5 and effects of corticosteroids in children treated for acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P20.	4.7	0
264	Ontogeny of cytochrome 3A and P-glycoprotein in the human intestine. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P50.	4.7	0
265	Immunohistochemical localisation and mRNA quantification of P-gp in human term placentas - no impact of corticosteroid administration for preterm labor. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P73.	4.7	0
266	1325 Intra-Subject Variability on 3T MRI Imaging of Neonatal Hips. <i>Archives of Disease in Childhood</i> , 2012, 97, A377-A378.	1.9	0
267	TINN (TREAT INFECTIONS IN NEONATES): AN FP7 PROJECT. <i>Clinical Therapeutics</i> , 2013, 35, e118-e119.	2.5	0
268	Pharmacologie des anti-infectieux en période néonatale. , 2015, , 187-196.		0
269	Approches méthodologiques en pharmacogénétique: le modèle des leucémies aiguës lymphoblastiques de l'enfant. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2015, 3, 215-220.	0.1	0
270	PHARMACOKINETIC STUDIES IN NEONATES: IS AN OPPORTUNISTIC SAMPLING STRATEGY SUFFICIENT FOR POPULATION PHARMACOKINETIC MODELLING AND DOSE PREDICTION?. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.11-e1.	1.9	0

#	ARTICLE	IF	CITATIONS
271	RISK FACTORS FOR NODAT UNDER IMMUNOSSUPPRESSANTS IN RENAL TRANSPLANTED CHILDREN. Archives of Disease in Childhood, 2016, 101, e1.44-e1.	1.9	0
272	PEDIATRIC DRUG TRIALS IN CHINA. Archives of Disease in Childhood, 2016, 101, e1.12-e1.	1.9	0
273	THE CLINICAL UTILITY AND SAFETY OF A MODEL-BASED PATIENT-TAILORED DOSE REGIMEN OF VANCOMYCIN IN NEONATES. Archives of Disease in Childhood, 2016, 101, e1.37-e1.	1.9	0
274	NEONATAL ADVERSE DRUG REACTIONS: ANALYSIS OF PHARMACOVIGILANCE REPORTS AFTER DIRECT DRUG EXPOSURE IN FRANCE. Archives of Disease in Childhood, 2016, 101, e1.22-e1.	1.9	0
275	DO WE HAVE A CONSENSUS TO APPLY MODEL-BASED AMINOGLYCOSIDE THERAPY: A REVIEW OF POPULATION PHARMACOKINETIC MODELS. Archives of Disease in Childhood, 2016, 101, e1.51-e1.	1.9	0
276	Les bases de pharmacologie du Développement. , 2017, , 43-48.		0
277	Aciclovir CSF concentration in children with viral encephalitis: is it adequate?. Journal of Antimicrobial Chemotherapy, 2018, 73, 2582-2583.	3.0	0
278	P30 Limited sampling strategies to predict valganciclovir exposure in kidney transplanted children. Archives of Disease in Childhood, 2019, 104, e29.2-e29.	1.9	0
279	P60 Serum Creatinine is superior to Serum Cystatin C in explaining inter-individual variability of vancomycin clearance in neonates and young infants. Archives of Disease in Childhood, 2019, 104, e42.1-e42.	1.9	0
280	Prevention and Management of Pain in Neonates. , 2006, , 409-415.		0
281	Monitoring Azathioprine Therapy in Paediatric Renal Transplant Recipients with Thiopurine Methyltransferase. Pediatric Research, 1999, 45, 65A-65A.	2.3	0
282	Ophthalmic insert for pupillary mydriasis in neonates. Acta Ophthalmologica, 2015, 93, n/a-n/a.	1.1	0
283	Ophthalmic insert for pupillary mydriasis in neonates. Acta Ophthalmologica, 2015, 93, n/a-n/a.	1.1	0
284	Analysis of Paediatric Clinical Trial Characteristics and Activity Over 23 Years Impact of the European Paediatric Regulation on a Single French Clinical Research Center. Frontiers in Pediatrics, 2022, 10, 842480.	1.9	0